Bone metastases in advanced urothelial carcinoma patients receiving enfortumab vedotin: A Real-World study from the ARON-2(EV) project.

Rizzo A, Myint ZW, Ciccimarra F, Zgura A, Matrana MR, Büttner T, Kopecky J, Vida AR, Rizzo M, Fujita K, Brunetti O, Santini D, Park SH, Formisano L, Poprach A, Kucharz J, Comes MC, Bove S, Fanizzi A, Massafra R, Cazzato G, Monteiro FSM, Mollica V, Massari F, Cerrillo JM, Santoni M

Open source

DOI: 10.1007/s10238-025-02020-3
Published: 2025 Dec 29
Container: Clinical and experimental medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s10238-025-02020-3,
  title = {Bone metastases in advanced urothelial carcinoma patients receiving enfortumab vedotin: A Real-World study from the ARON-2(EV) project.},
  author = {Rizzo A and Myint ZW and Ciccimarra F and Zgura A and Matrana MR and Büttner T and Kopecky J and Vida AR and Rizzo M and Fujita K and Brunetti O and Santini D and Park SH and Formisano L and Poprach A and Kucharz J and Comes MC and Bove S and Fanizzi A and Massafra R and Cazzato G and Monteiro FSM and Mollica V and Massari F and Cerrillo JM and Santoni M},
  year = {2025},
  journal = {Clinical and experimental medicine},
  doi = {10.1007/s10238-025-02020-3},
  url = {https://doi.org/10.1007/s10238-025-02020-3}
}

RIS

TY  - JOUR
TI  - Bone metastases in advanced urothelial carcinoma patients receiving enfortumab vedotin: A Real-World study from the ARON-2(EV) project.
AU  - Rizzo A
AU  - Myint ZW
AU  - Ciccimarra F
AU  - Zgura A
AU  - Matrana MR
AU  - Büttner T
AU  - Kopecky J
AU  - Vida AR
AU  - Rizzo M
AU  - Fujita K
AU  - Brunetti O
AU  - Santini D
AU  - Park SH
AU  - Formisano L
AU  - Poprach A
AU  - Kucharz J
AU  - Comes MC
AU  - Bove S
AU  - Fanizzi A
AU  - Massafra R
AU  - Cazzato G
AU  - Monteiro FSM
AU  - Mollica V
AU  - Massari F
AU  - Cerrillo JM
AU  - Santoni M
PY  - 2025
JO  - Clinical and experimental medicine
DO  - 10.1007/s10238-025-02020-3
UR  - https://doi.org/10.1007/s10238-025-02020-3
ER  -

APA

A, R., ZW, M., F, C., A, Z., MR, M., T, B., J, K., AR, V., M, R., K, F., O, B., D, S., SH, P., L, F., A, P., J, K., MC, C., S, B., A, F., R, M., G, C., FSM, M., V, M., F, M., JM, C., & M, S. (2025). Bone metastases in advanced urothelial carcinoma patients receiving enfortumab vedotin: A Real-World study from the ARON-2(EV) project.. Clinical and experimental medicine. https://doi.org/10.1007/s10238-025-02020-3

Source records

pubmed · retrieved 2026-09-27T07:48:24.417Z
europe-pmc · retrieved 2026-09-27T07:48:24.425Z